Structure-based design of thienobenzoxepin inhibitors of PI3-kinase.
Staben, S.T., Siu, M., Goldsmith, R., Olivero, A.G., Do, S., Burdick, D.J., Heffron, T.P., Dotson, J., Sutherlin, D.P., Zhu, B.Y., Tsui, V., Le, H., Lee, L., Lesnick, J., Lewis, C., Murray, J.M., Nonomiya, J., Pang, J., Prior, W.W., Salphati, L., Rouge, L., Sampath, D., Sideris, S., Wiesmann, C., Wu, P.(2011) Bioorg Med Chem Lett 21: 4054-4058
- PubMed: 21636270 
- DOI: https://doi.org/10.1016/j.bmcl.2011.04.124
- Primary Citation of Related Structures:  
3R7Q, 3R7R - PubMed Abstract: 
Starting from thienobenzopyran HTS hit 1, co-crystallization, molecular modeling and metabolic analysis were used to design potent and metabolically stable inhibitors of PI3-kinase. Compound 15 demonstrated PI3K pathway suppression in a mouse MCF7 xenograft model.
Organizational Affiliation: 
Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. stevents@gene.com